Precision Medicine News and Research

RSS

UCLA study reveals key signs for genetic testing in neurodevelopment disorders

In a new study, UCLA Health researchers have found that motor delay and low muscle tone were common signs of an underlying genetic diagnosis in children with neurodevelopment disorders.

12 Oct 2024

Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).

10 Oct 2024

Study illuminates the origin and progression of bladder cancer

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center.

9 Oct 2024

Liver cancer patients gain clarity on surgery options through precision medicine tool

Duke-NUS alumnus Dr Marjorie Hoang (Class of 2023) and her mentor, Professor Pierce Chow, have brought clarity to the complex decision-making process patients diagnosed with intermediate-stage liver cancer and their doctors face by creating an algorithm that can accurately calculate the likely overall survival and recurrence-free survival following surgery.

9 Oct 2024

Deciphering the Mysteries of the Human Microbiome

The Microsetta Initiative studies human microbiomes, analyzing diverse data to reveal links between microbes, diet, and health for improved public health.

8 Oct 2024

AI and imaging tools to drive personalized cancer treatments in Europe

Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies ("Theranostics") to target cancer first at the "diagnosis" phase and then at the "therapy" phase, using the same biological targets ("see to treat").

8 Oct 2024

Owkin partners with AstraZeneca to enhance gBRCA testing for breast cancer

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

4 Oct 2024

The impact of KRAS mutations on pancreatic cancer progression and survival

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center, and other institutions.

3 Oct 2024

Scientists overcome major challenge in gene therapy and drug delivery

Imagine trying to poke a hole in the yolk of a raw egg without breaking the egg white. It sounds impossible, but researchers at the University of California San Diego have developed a technology that performs a similarly delicate task in living cells. They created an array of nanopillars that can breach the nucleus of a cell - the compartment that houses our DNA - without damaging the cell's outer membrane.

3 Oct 2024

Study highlights the role of genetic factors in COVID-19 thrombosis and inflammation

Despite global vaccination efforts, COVID-19 continues to pose significant risks, leading to severe complications and fatalities. These risks are driven by disrupted coagulation, impaired fibrinolysis, which is the process of breaking blood clots, and heightened inflammatory responses.

3 Oct 2024

FDA approves new PET imaging agent for coronary artery disease

The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients with known or suspected coronary artery disease (CAD).

1 Oct 2024

Novel lipid nanoparticles enhance tissue-specific drug delivery

Penn Engineers have discovered a novel means of directing lipid nanoparticles (LNPs), the revolutionary molecules that delivered the COVID-19 vaccines, to target specific tissues, presaging a new era in personalized medicine and gene therapy.

1 Oct 2024

Targeted drug therapy shows promise for ulcerative colitis remission

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.

26 Sep 2024

Stool-based testing offers a new hope for global colorectal cancer screening

"Stool-based test offers a promising solution to reduce the burden of a colonoscopy," experts emphasized on September 21st, during the ICG 19 · Metagenomics for Health (ICG19·MH) & The 2nd MOHA Consortium. The conference was held in Harbin, Heilongjiang Province of China.

25 Sep 2024

UCLA develops largest collection of patient-derived organoids for sarcoma research

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

20 Sep 2024

Enhancing patient outcomes with AI-driven intratumoral immunotherapy

A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, "The emerging role of AI in enhancing intratumoral immunotherapy care."

19 Sep 2024

Study reveals MYC gene's role in prostate cancer initiation and progression

By tracking the changes in prostate cancer cells over time, researchers at the Johns Hopkins Kimmel Cancer Center have found that activation of the MYC gene - a well-known cancer-causing gene - sets off a cascade of events that leads to both initiation and progression of the disease.

19 Sep 2024